Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its proprietary Gene Circuit platform, has announced an upcoming presentation. Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025, at 2:40 PM ET.
Senti Biosciences (NASDAQ: SNTI) has received an additional $1.0 million from the California Institute for Regenerative Medicine (CIRM) after achieving clinical study enrollment milestones. This brings the total received to $7.4 million of the $8.0 million grant supporting SENTI-202 development.
SENTI-202, a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, targets CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells. In its ongoing Phase 1 trial, preliminary results showed the therapy was well-tolerated with no dose-limiting toxicities. The preliminary recommended Phase 2 dose was set at 1.5 x 109 CAR NK cells.
Notable efficacy results include: 2 of 3 patients achieving composite Complete Remission (cCR) in the preliminary RP2D cohort, 5 of 7 patients achieving Overall Response Rate across all dose levels, and 4 of 4 cCR patients achieving MRD-negative status, with the longest response lasting 8+ months.
The trial showed SENTI-202 was well-tolerated with 4 out of 7 patients achieving composite Complete Remission (cCR). All cCR patients were MRD negative and maintained responses ranging from 4+ to 8+ months. The preliminary recommended Phase 2 dose was identified at 1.5 x 109 CAR NK cells.
Financial results for Q1 2025 showed cash and cash equivalents of $33.8 million. R&D expenses increased to $9.3 million from $8.8 million year-over-year, while G&A expenses decreased to $7.1 million from $7.5 million. The company reported a net loss of $14.1 million ($1.41 per share).
Senti Biosciences (NASDAQ: SNTI) has released a Virtual Investor segment featuring Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, discussing recently presented positive preliminary Phase 1 clinical trial data for SENTI-202 at AACR Annual Meeting 2025.
SENTI-202 is a pioneering off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotech company focused on next-generation cell and gene therapies, has announced its upcoming presentation at the Citizens JMP Life Sciences Conference in New York. The presentation is scheduled for May 8th, 2025, at 1:00 PM ET.
Dr. Timothy Lu, Co-Founder and CEO, will lead the presentation, which will highlight recent positive preliminary clinical results of their lead program, SENTI-202, in treating patients with Relapsed/Refractory AML. Management will also be available for one-on-one meetings with qualified investors attending the conference.
Interested parties can access the live video webcast through Senti Bio's website investor section and will remain available for 90 days after the event.
Senti Bio (NASDAQ: SNTI) has reported positive preliminary results from its Phase 1 clinical trial of SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy for treating relapsed/refractory AML. The data was presented at the AACR Annual Meeting 2025.
Key findings include:
- 5 of 7 evaluable patients achieved overall response rate across all dose cohorts
- 4 of 4 complete remission patients were measurable residual disease negative
- Longest durability observed at 8+ months
- No dose limiting toxicities reported
- Preliminary recommended Phase 2 dose identified as 1.5 x 109 CAR NK cells
The company reported Q1 2025 preliminary financials with cash and equivalents of $33.8 million, R&D expenses of $9.3 million, and a net loss of $14.1 million ($1.41 per share). Additionally, Senti Bio announced the stoppage of enrollment in their SENTI-301A trial for HCC due to dose limiting toxicities.
Senti Biosciences (SNTI) announced it will host a conference call and webcast on Monday, April 28, 2025 at 8:30 AM ET to discuss new Phase 1 clinical data for SENTI-202 being presented at the American Association for Cancer Research (AACR) Annual Meeting.
The presentation will be led by CEO and Co-Founder Timothy Lu, MD, PhD, and President, Head of R&D and Chief Medical Officer Kanya Rajangam, MD, PhD. Participants can join via phone at (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). The webcast will be available on the company's website and archived for 90 days.